Avacta Group (LON:AVCT) Sets New 12-Month Low - Time to Sell?

Avacta Group Plc (LON:AVCT - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 28.83 ($0.38) and last traded at GBX 35.50 ($0.46), with a volume of 4674920 shares changing hands. The stock had previously closed at GBX 33.44 ($0.44).

Avacta Group Stock Up 0.8 %

The firm has a fifty day simple moving average of GBX 39.59 and a 200-day simple moving average of GBX 46.72. The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The company has a market capitalization of £145.57 million, a P/E ratio of -4.93 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).